#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurofibroma Hepatocellular carcinoma CDKL5 deficiency disorder Polycythaemia vera Epstein-Barr virus associated lymphoproliferative disorder Leukaemia Eosinophilic oesophagitis Chronic graft versus host disease in intestine Arrhythmia Uterine leiomyosarcoma Antiphospholipid antibodies Immune-mediated myositis Infertility male Erythema multiforme Renal cancer metastatic More trials…

    Learn about Rare Diseases

    Congenital nephrogenic diabetes insipidus Ornithine transcarbamoylase deficiency – Treatment Progressive supranuclear palsy – Trials in Disease Pituitary-dependent Cushing’s syndrome – Trials in Disease Ewing’s sarcoma metastatic – Life with Disease Hereditary optic atrophy – Treatment Von Willebrand’s disease – Trials in Disease Breast angiosarcoma metastatic – Trials in Disease Basal cell naevus syndrome – Trials in Disease Tuberous sclerosis complex – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxazepam MOLNUPIRAVIR Adg126 Ascorbic Acid Bp Keto-Isoleucine Calcium Dicloxacillin Osimertinib Ralinepag Gs-5245 Gskvx000000008866 Olopatadine Hydrochloride Vortioxetine Hydrobromide Gremubamab Temozolomide Dazucorilant Dotatate LIGUFALIMAB Esmolol Hydrochloride Apg777 Ima402 More therapies…

    Learn about Your Condition

    VEXAS syndrome Hypothyroidism Hyperlipidaemia Sarcoma metastatic Tissue anoxia Immune thrombocytopenia Hypertonic bladder Anaemia of pregnancy Acute myocardial infarction Haemodialysis Postpartum haemorrhage Lower limb fracture Oropharyngeal cancer Prodromal Alzheimer's disease Bone marrow failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma

  • Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    • Pembrolizumab
    The Netherlands

  • Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dacarbazine
    • Doxycycline Monohydrate
    • Dacarbazine Citrate
    Belgium Czechia Denmark France Germany Italy +4

  • Study of MaaT013 (Fecal Transplantation) Combined with Ipilimumab and Nivolumab in Patients with Previously Untreated Melanoma

    Not recruiting

    2 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Allogeneic Faecal Microbiota, Pooled
    France

  • Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    Austria France Germany Greece Ireland Italy +2

  • Study on Atezolizumab and Tiragolumab for Patients with Head and Neck Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Neoplasm malignant
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    The Netherlands

  • Study on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Tebentafusp
    • Dacarbazine
    • Ipilimumab
    Belgium France Italy Poland Spain
Previous Page
1 … 6 7 8 9 10 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!